LifeArc bolsters executive team with communications expertise

Welcome to Anna Tomlinson, who joins LifeArc as our first Chief Communications Officer. Anna will join and…

£100m programme to transform care for people living with chronic lung conditions

More than 300,000 people in the UK are living with bronchiectasis and more than 10,000 have been diagnosed with cystic fibrosis.

LifeArc responds to the Government’s renewed pledge to increase R&D funding

LifeArc CEO Dr Melanie Lee welcomes the Government’s restatement of its commitment to increase R&D funding in today’s Autumn statement: “Today the Chancellor made it clear that UK life science is a key driver of growth. “I am delighted that promises to raise the research and development (R&D) budget have been protected. It is the […]

LifeArc plays key role in discovery of new Alzheimer’s treatment

LifeArc played an important part in the discovery of lecanemab, an experimental drug that has shown some benefits for people with early Alzheimer’s disease.

LifeArc funds home monitoring trials for people with chronic respiratory conditions

Trials will examine the impact of home monitoring and machine learning decision support algorithms for people with CF and bronchiectasis.

LifeArc Ventures invests in Surgery Hero, world’s first digital coaching clinic for patients

Seed funding will be used to scale the solution through the application of machine learning

Call for Government to place medical research at the heart of economic plans

Ahead of the Autumn Statement, LifeArc and other leading life science organisations have written to the Chancellor…

LifeArc contributes to organic chemistry breakthrough

The findings reveal that seemingly impossible chemical reactions can be driven through a phenomenon called quantum tunnelling.

AbbVie acquires LifeArc portfolio company DJS Antibodies

AbbVie will pay DJS shareholders approximately $255 million in cash at closing for the acquisition of DJS